

05 Nov 2023 | News

# Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: CEOs on global tensions; Roche's new Alzheimer's contender; Sanofi eyes external deals; investors' reactions to clinical data; and Korean licensing pitfalls

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 3 November 2023, including: CEOs on global tensions; Roche's new Alzheimer's contender; Sanofi eyes external deals; investors' reactions to clinical data; and Korean licensing pitfalls

This and all our other podcasts are available on the *Citeline* channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[A Gloomy Outlook On Macro Trends From Industry CEOs](#)" - Scrip, 1 Nov, 2023.)

(Also see "[CTAD 2023: Roche's Trontinemab Shows Rapid, Deep Amyloid Clearance Lacking From Gantenerumab](#)" - Scrip, 26 Oct, 2023.)

(Also see "[Sanofi Eyes External Deals On Top Of Promising Pipeline](#)" - Scrip, 30 Oct, 2023.)

(Also see "[Tempest Changes The Atmosphere](#)" - Scrip, 31 Oct, 2023.)

(Also see "[How Korea Can Avoid Pitfalls Of Over-Reliance On Out-Licensing](#)" - Scrip, 30 Oct, 2023.)

[Click here to explore this interactive content online](#) 